Digestive Diseases and Sciences

, Volume 55, Issue 5, pp 1406–1412 | Cite as

The Prevalence and Clinical Significance of Perinuclear Anti-neutrophil Cytoplasmic Antibody in Korean Patients with Ulcerative Colitis

  • Jin Ha Lee
  • Jae Hee CheonEmail author
  • Eun Soo Kim
  • Moon Jae Chung
  • Wonseok Kang
  • Duk Hwan Kim
  • You Jung Ha
  • Jae Jun Park
  • Tae Il Kim
  • Won Ho Kim
Original Article


Perinuclear anti-neutrophil cytoplasmic antibody (pANCA) is a serological marker associated with various immune-mediated diseases whose clinical significance and possible diagnostic roles in ulcerative colitis (UC) are still unclear. We aimed to evaluate the prevalence of pANCA expression and its association with clinical findings and disease course in Korean patients with UC. This study included 484 patients with UC who were diagnosed and treated between 1990 and 2006 at Severance Hospital, Yonsei University, Seoul, Korea, and were followed for at least 1 year. Clinical findings at diagnosis, disease extent, treatment modalities used, and cumulative relapse rates were analyzed and compared to pANCA expression. Of the 484 patients, 405 (83.7%) were evaluated for pANCA and were eligible for analysis. The overall pANCA prevalence was 22.1%, with a female preponderance (male, 21.5%; female, 31.6%; P < 0.05). Proctitis was more common in pANCA-negative patients (pANCA-negative, 37.6%; pANCA-positive, 25.2%, P < 0.05). UC activity index and cumulative relapse rates were higher in pANCA-positive patients. However, there were no significant differences in the cumulative probability of steroid and immunosuppressant use and operation rate between the two groups. The prevalence of pANCA expression in Korean patients with UC was relatively low compared to that in Western countries. Although UC patients with pANCA expression had more severe clinical findings at diagnosis and higher cumulative relapse rates in our study, further prospective studies are warranted to clarify whether pANCA positivity influences the initial clinical presentation or disease aggressiveness.


Disease activity Korean pANCA Prevalence Ulcerative colitis 


  1. 1.
    Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205. doi: 10.1016/S0016-5085(98)70381-6.CrossRefPubMedGoogle Scholar
  2. 2.
    Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429. doi: 10.1056/NEJMra020831.CrossRefPubMedGoogle Scholar
  3. 3.
    Roozendaal C, Kallenberg CG. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin Exp Immunol. 1999;116:206–213. doi: 10.1046/j.1365-2249.1999.00905.x.CrossRefPubMedGoogle Scholar
  4. 4.
    Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202–210. doi: 10.1016/S0091-6749(05)80067-3.CrossRefPubMedGoogle Scholar
  5. 5.
    Rump JA, Scholmerich J, Gross V, Roth M, Helfesrieder R, Rautmann A, Lüdemann J, Gross WL, Peter HH. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn’s disease. Immunobiology. 1990;181:406–413.PubMedGoogle Scholar
  6. 6.
    Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti-saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis. 2003;35:862–868. doi: 10.1016/j.dld.2003.07.001.CrossRefPubMedGoogle Scholar
  7. 7.
    Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006;368:404–418. doi: 10.1016/S0140-6736(06)69114-9.CrossRefPubMedGoogle Scholar
  8. 8.
    Sobajima J, Ozaki S, Okazaki T, Osakada F, Sumita S, Mori K, Nakao K. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol. 1996;105:120–124. doi: 10.1046/j.1365-2249.1996.d01-724.x.CrossRefPubMedGoogle Scholar
  9. 9.
    Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71:431–436. doi: 10.4065/71.5.431.CrossRefPubMedGoogle Scholar
  10. 10.
    Oudkerk Pool M, Ellerbroek PM, Ridwan BU, Goldschmeding R, von Blomberg BM, Peña AS, Dolman KM, Bril H, Dekker W, Nauta JJ. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut. 1993;34:46–50. doi: 10.1136/gut.34.1.46.CrossRefPubMedGoogle Scholar
  11. 11.
    O’Morain C, Tobin A, Leen E, Suzuki Y, O’Riordan T. Criteria of case definition in Crohn’s disease and ulcerative colitis. Scand J Gastroenterol Suppl. 1989;170:7–11. doi: 10.3109/00365528909091340. discussion 16–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833–837.CrossRefPubMedGoogle Scholar
  13. 13.
    D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–786. doi: 10.1053/j.gastro.2006.12.038.CrossRefPubMedGoogle Scholar
  14. 14.
    Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–1209. doi: 10.1111/j.1572-0241.2007.01756.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang YF, Zhang H, Ouyang Q. Clinical manifestations of inflammatory bowel disease: East and West differences. J Dig Dis. 2007;8:121–127. doi: 10.1111/j.1443-9573.2007.00296.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753. doi: 10.1136/gut.2005.082909.CrossRefPubMedGoogle Scholar
  17. 17.
    Kuriyama M, Kato J, Fujimoto T, Nasu J, Miyaike J, Morita T, Okada H, Suzuki S, Shiode J, Yamamoto H, Shiratori Y. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient’s clinical background. Dis Colon Rectum. 2006;49:1307–1315. doi: 10.1007/s10350-006-0574-6.CrossRefPubMedGoogle Scholar
  18. 18.
    Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J Autoimmun. 1997;10:175–180. doi: 10.1006/jaut.1996.0114.CrossRefPubMedGoogle Scholar
  19. 19.
    Lok KH, Hung HG, Ng CH, Kwong KC, Yip WM, Lau SF, Li KK, Li KF, Szeto ML. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008;23:406–410. doi: 10.1111/j.1440-1746.2007.05079.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Osangthamnont C, Manatsathit S, Pongprasopchai S, Viriyataveekul R, Chaihirunkarn S, Leelakusolvong S, Boonyapisit S. Antibodies to neutrophil cytoplasma in patients with ulcerative colitis and their first-degree relatives in Thailand. J Gastroenterol Hepatol. 2001;16:866–871. doi: 10.1046/j.1440-1746.2001.02546.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Yamamoto-Furusho JK, Takahashi-Monroy T, Vergara-Fernandez O, Reyes E, Uscanga L. Perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in chronic ulcerative colitis: experience in a Mexican Institution. World J Gastroenterol. 2006;12:3406–3409.PubMedGoogle Scholar
  22. 22.
    Sung JY, Chan KL, Hsu R, Liew CT, Lawton JW. Ulcerative colitis and antineutrophil cytoplasmic antibodies in Hong Kong Chinese. Am J Gastroenterol. 1993;88:864–869.PubMedGoogle Scholar
  23. 23.
    Perri F, Annese V, Piepoli A, Napolitano G, Lombardi G, Ciavarella G, Di Giorgio G, Andriulli A. HLA antigens and pANCA define ulcerative colitis as a genetically heterogeneous disorder. Ital J Gastroenterol Hepatol. 1998;30:56–61.PubMedGoogle Scholar
  24. 24.
    Duerr RH, Neigut DA. Molecularly defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology. 1995;108:423–427. doi: 10.1016/0016-5085(95)90069-1.CrossRefPubMedGoogle Scholar
  25. 25.
    Yang H, Rotter JI, Toyoda H, Landers C, Tyran D, McElree CK, Targan SR. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest. 1993;92:1080–1084. doi: 10.1172/JCI116613.CrossRefPubMedGoogle Scholar
  26. 26.
    Park SH, Kim YM, Yang SK, Kim SH, Byeon JS, Myung SJ, Cho YK, Yu CS, Choi KS, Chung JW, Kim B, Choi KD, Kim JH. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13:278–283. doi: 10.1002/ibd.20015.CrossRefPubMedGoogle Scholar
  27. 27.
    Maunder RG, Lancee WJ, Greenberg GR, Hunter JJ, Fernandes BJ. Insecure attachment in a subgroup with ulcerative colitis defined by ANCA status. Dig Dis Sci. 2000;45:2127–2132. doi: 10.1023/A:1026471303921.CrossRefPubMedGoogle Scholar
  28. 28.
    Maunder RG, Greenberg GR, Hunter JJ, Lancee WJ, Steinhart AH, Silverberg MS. Psychobiological subtypes of ulcerative colitis: pANCA status moderates the relationship between disease activity and psychological distress. Am J Gastroenterol. 2006;101:2546–2551.PubMedGoogle Scholar
  29. 29.
    Fujimoto T, Kato J, Nasu J, Kuriyama M, Okada H, Yamamoto H, Mizuno M, Shiratori Y; Japan West Ulcerative Colitis (JWUC) Study Group. Change of clinical characteristics of ulcerative colitis in Japan: analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol Hepatol. 2007;19:229–235. doi: 10.1097/MEG.0b013e3280110fb9.CrossRefPubMedGoogle Scholar
  30. 30.
    Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408–413.PubMedGoogle Scholar
  31. 31.
    Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol. 2002;8:158–161.PubMedGoogle Scholar
  32. 32.
    Radhakrishnan S, Zubaidi G, Daniel M, Sachdev GK, Mohan AN. Ulcerative colitis in Oman. A prospective study of the incidence and disease pattern from 1987 to 1994. Digestion. 1997;58:266–270. doi: 10.1159/000201453.CrossRefPubMedGoogle Scholar
  33. 33.
    Benfield GF, Montgomery RD, Asquith P. Ulcerative colitis in Asian immigrants. Postgrad Med J. 1987;63:629–635. doi: 10.1136/pgmj.63.742.629.CrossRefPubMedGoogle Scholar
  34. 34.
    Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998;93:1867–1872. doi: 10.1111/j.1572-0241.1998.540_i.x.CrossRefPubMedGoogle Scholar
  35. 35.
    Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1193–1196. doi: 10.1111/j.1572-0241.2007.01700.x.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jin Ha Lee
    • 1
  • Jae Hee Cheon
    • 1
    Email author
  • Eun Soo Kim
    • 1
  • Moon Jae Chung
    • 1
  • Wonseok Kang
    • 1
  • Duk Hwan Kim
    • 1
  • You Jung Ha
    • 1
  • Jae Jun Park
    • 1
  • Tae Il Kim
    • 1
  • Won Ho Kim
    • 1
  1. 1.Department of Internal Medicine and Institute of GastroenterologyYonsei University College of MedicineSeoulKorea

Personalised recommendations